City
Epaper

Patanjali launches Ayurvedic COVID-19 medicine, claims 100 pc recovery within 3-7 days

By ANI | Updated: June 23, 2020 13:55 IST

Patanjali on Tuesday launched 'Coronil and Swasari', what it claims is the Ayurvedic cure for treating COVID-19, which they said has been shown 100 per cent favourable results during clinical trials on affected patients, at Patanjali Yogpeeth here.

Open in App

Patanjali on Tuesday launched 'Coronil and Swasari', what it claims is the Ayurvedic cure for treating COVID-19, which they said has been shown 100 per cent favourable results during clinical trials on affected patients, at Patanjali Yogpeeth here.

The efficacy of Patanjali's medicine on Covid cure has not been corroborated by any independent medical body as of yet. The World Health Orgzation (WHO) had recently said that while several drug trials are ongoing, there is currently no proof that any drug can cure or prevent COVID-19. The orgsation had added that it was coordinating efforts to develop and evaluate medicines to treat COVID-19.

"The whole country and the world was waiting for medicine or vaccine for corona. We are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS," Yoga Guru Ramdev said at the press conference here adding that it has shown "100 per cent recovery rate within 3-7 days."

"We are launching COVID medicines Coronil and Swasari today. We conducted two trials of these, first clinical controlled study, which took place in Delhi, Ahmedabad, among many other cities. Under this 280 patients were included and 100 per cent of those recovered. We were able to control Corona and its complications in this. After this the all-important clinical control trial was conducted," he added.

He thanked the Director, National Institute of Medical Sciences, NIMS University, Jaipur, Dr Balbir Singh Tomar and all other doctors and scientists for their help in creating the medicine.

"With the help of NIMS, Jaipur we conducted the clinical control study on 95 patients. The biggest thing which came out of this is that within three days 69 per cent patients recovered and became negative from positive (cases) and within seven days 100 per cent of them became negative," he added.

He also said that necessary approvals for conducting the trials of medicine on patients had been taken from competent authorities.

Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, was also present at the occasion of the launch along with other officials and representatives who had taken part in the preparation of the medicine.

With an increase of 14,933 new cases and 312 deaths in the last 24 hours, India's COVID-19 count reached 4,40,215 on Tuesday.

According to the latest update by the Union Ministry of Health and Family Welfare (MoHFW), 14,011 deaths have been recorded due to the infection so far in the country.

( With inputs from ANI )

Tags: Patanjali research centreBalbir singh tomardelhiJaipurNims`delhi
Open in App

Related Stories

NationalDelhi Horror: 28-Year-Old Youth Beaten to Death by Man Over Minor Argument; Accused Arrested

NationalDelhi Shooting Incident: Two Brothers Killed After Firing in Jaffrabad; Police Investigation Underway

CricketJay Shah Gifts Lionel Messi Special Jersey, Bat and ICC T20 World Cup 2026 Match Ticket During His GOAT India Tour in Delhi

NationalDelhi Traffic Update: Police Issue Diversions and Restrictions Ahead of Lionel Messi’s GOAT India Tour Event at Arun Jaitley Stadium

NationalWatch: Toxic Smog Blankets Delhi’s Anand Vihar as City Grapples with Severe AQI

National Realted Stories

NationalAssam CM greets people of Goa on Liberation Day, recalling sacrifices for freedom

NationalBengal SIR: Number of applications from new voters negligible compared to those excluded

NationalKerala LoP Satheesan writes to Meta, requesting not to block viral Sabarimala gold theft parody song

NationalJ&K braces for rain, snow in next 48 hours; two-month dry spell likely to break

NationalPMVBRY aims to incentivise creation of over 3.5 crore jobs over 2 years